Sgrulletti Mayla, Ottaviano Giorgio, Sangerardi Maria, Chini Loredana, Dellepiane Rosa Maria, Martire Baldassarre, Montin Davide, Rizzo Caterina, Moschese Viviana
Pediatric Immunopathology and Allergology Unit, University of Rome Tor Vergata, Policlinico Tor Vergata, Rome, Italy.
Molecular and Cellular Immunology Unit, Great Ormond Street Institute of Child Health, University College of London, London, UK.
Pediatr Allergy Immunol. 2020 Nov;31 Suppl 26(Suppl 26):69-71. doi: 10.1111/pai.13338.
Flu virus infection is a common cause of acute respiratory illness, with the major incidence in pediatric age, high morbidity, and mortality. The flu vaccine is recommended for all people aged ≥6 months, unless specific contraindications are present. Younger and older age, pregnancy, chronic diseases like asthma, and immunodeficiency are risk factors for severe complications following flu infection. Thus, these categories represent the target for flu vaccine strategies in most countries. Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) or live-attenuated influenza virus (LAIV) are currently available, with specific precautions and contraindications. We aim to resume the current indications for vaccines in the vulnerable populations to support flu vaccination inclusiveness, in anticipation of a "universal vaccine" strategy.
流感病毒感染是急性呼吸道疾病的常见病因，主要发病于儿童期，发病率和死亡率都很高。建议所有6个月及以上的人群接种流感疫苗，除非存在特定的禁忌证。年龄较小和较大、怀孕、哮喘等慢性疾病以及免疫缺陷是流感感染后发生严重并发症的危险因素。因此，在大多数国家，这些人群是流感疫苗接种策略的目标对象。目前有灭活流感疫苗（IIV）、重组流感疫苗（RIV）或减毒活流感病毒疫苗（LAIV），接种时有特定的注意事项和禁忌证。我们的目标是恢复目前针对脆弱人群的疫苗接种适应证，以支持流感疫苗接种的包容性，期待“通用疫苗”策略的出现。
